|
Capless and Tailless Therapeutic Exogenous mRNA for Vaccine Development
Opportunity
The approval and distribution of messenger RNA (mRNA) vaccines to successfully control the SARS-CoV-2 pandemic in 2021 exposed a major market for vaccine innovation and mRNA-based therapies. The mRNA used for treatment or vaccination is produced with a protecting 5’ cap and a 3’ poly-A tail at each end of the mRNA molecule....
Inventor(s): Brian Fouty, Victor Solodushko
Category(s): All Technologies, Antibody, Therapeutics, Vaccines, Gene Therapy and Delivery
|
